Skip to main content

Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes.

Publication ,  Journal Article
Nathan, SD; Deng, C; King, CS; DuBrock, HM; Elwing, J; Rajagopal, S; Rischard, F; Sahay, S; Broderick, M; Shen, E; Smith, P; Tapson, VF; Waxman, AB
Published in: Chest
February 2023

BACKGROUND: Pulmonary hypertension (PH) complicates the course of many patients with fibrotic interstitial lung disease (ILD). Inhaled treprostinil (iTre) has been shown to improve functional ability and to delay clinical worsening in patients with PH resulting from ILD. RESEARCH QUESTION: Do higher dosages of iTre have greater benefits in preventing clinical worsening and achieving clinical improvement? STUDY DESIGN AND METHODS: Post hoc analysis of the INCREASE study, a 16-week double-blind, randomized, placebo-controlled trial of iTre in patients with PH resulting from ILD. Four groups were identified based on the number of breaths per session (bps; < 9 and ≥ 9 bps) of active drug or placebo attained at 4 weeks. Patients were evaluated for clinical worsening (15% decrease in 6-min walkdistance, cardiopulmonary hospitalization, lung transplantation, or death) or clinical improvement (15% increase in the six-minute walk distance with a concomitant 30% reduction in N-terminal prohormone of brain natriuretic peptide without any clinical worsening event). RESULTS: At 4 weeks, 70 patients were at a dose of ≥ 9 bps (high-dosage group) and 79 patients were at a dose of < 9 bps (low-dosage group) in the iTre arm vs 86 patients in the high-dose group and 67 patients in the low-dose group in the placebo arm. Between weeks 4 and 16, 17.1% of patients in the high-dose treprostinil group and 22.8% in the low-dose treatment group experienced a clinical worsening event vs 33.7% and 34.3% of patients in the two placebo arms, respectively (P = .006). By week 16, 15.7% and 12.7% of patients in the high- and low-dose iTre groups, respectively, demonstrated clinical improvement vs 7% and 1.5% patients in the placebo arms (P = .003) INTERPRETATION: Higher dosages of iTre overall show greater benefit in terms of preventing clinical worsening and achieving clinical improvement. These data support the early initiation and uptitration of therapy to a dosage of at least 9 bps four times daily in patients with PH resulting from ILD. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02630316; URL: www. CLINICALTRIALS: gov.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Chest

DOI

EISSN

1931-3543

Publication Date

February 2023

Volume

163

Issue

2

Start / End Page

398 / 406

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Respiratory System
  • Lung Diseases, Interstitial
  • Hypertension, Pulmonary
  • Humans
  • Epoprostenol
  • Double-Blind Method
  • Antihypertensive Agents
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nathan, S. D., Deng, C., King, C. S., DuBrock, H. M., Elwing, J., Rajagopal, S., … Waxman, A. B. (2023). Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes. Chest, 163(2), 398–406. https://doi.org/10.1016/j.chest.2022.09.007
Nathan, Steven D., Chunqin Deng, Christopher S. King, Hilary M. DuBrock, Jean Elwing, Sudarshan Rajagopal, Franz Rischard, et al. “Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes.Chest 163, no. 2 (February 2023): 398–406. https://doi.org/10.1016/j.chest.2022.09.007.
Nathan SD, Deng C, King CS, DuBrock HM, Elwing J, Rajagopal S, et al. Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes. Chest. 2023 Feb;163(2):398–406.
Nathan, Steven D., et al. “Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes.Chest, vol. 163, no. 2, Feb. 2023, pp. 398–406. Pubmed, doi:10.1016/j.chest.2022.09.007.
Nathan SD, Deng C, King CS, DuBrock HM, Elwing J, Rajagopal S, Rischard F, Sahay S, Broderick M, Shen E, Smith P, Tapson VF, Waxman AB. Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes. Chest. 2023 Feb;163(2):398–406.

Published In

Chest

DOI

EISSN

1931-3543

Publication Date

February 2023

Volume

163

Issue

2

Start / End Page

398 / 406

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Respiratory System
  • Lung Diseases, Interstitial
  • Hypertension, Pulmonary
  • Humans
  • Epoprostenol
  • Double-Blind Method
  • Antihypertensive Agents
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology